₩ 171100
Key Takeaways
Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Target Price
The average target price of 068270.KS is 224453 and suggests 31% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
